Evidence map›Paper›PMID 41078831›Full record

ArticleACS omega2025

Sustainable Synthesis of Silver Nanoparticles (Chemical vs Biological) and Their Antimicrobial Activity against Clinical Pathogens.

Flávia Satie Noguti, Matheus Felipe Celestino, Lucas Teixeira Mori, Jaqueline Portes Pagnoncelli Martins, Giani Andrea Linde, Nelson Barros Colauto, Cleverson Busso, Renato Eising

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Flávia Satie NogutiUniversidade Tecnológica Federal do Paraná (UTFPR), Graduate Program in Bioscience Technologies, Toledo, Paraná 85902-490, Brazil.
Matheus Felipe CelestinoUniversidade Tecnológica Federal do Paraná (UTFPR), Graduate Program in Bioscience Technologies, Toledo, Paraná 85902-490, Brazil.
Lucas Teixeira MoriUniversidade Tecnológica Federal do Paraná (UTFPR), Graduate Program in Bioscience Technologies, Toledo, Paraná 85902-490, Brazil.
Jaqueline Portes Pagnoncelli MartinsUniversidade Estadual do Oeste do Paraná (Unioeste), Graduate Program in Chemistry, Toledo, Paraná 85903-220, Brazil.
Giani Andrea LindeCentro Universitário UNIFATECIE, Paranavaí, Paraná 87720-140, Brazil.
Nelson Barros ColautoUniversidade Tecnológica Federal do Paraná (UTFPR), Graduate Program in Bioscience Technologies, Toledo, Paraná 85902-490, Brazil.ORCID https://orcid.org/0000-0003-4390-8302
Cleverson BussoUniversidade Tecnológica Federal do Paraná (UTFPR), Graduate Program in Bioscience Technologies, Toledo, Paraná 85902-490, Brazil.
Renato EisingUniversidade Tecnológica Federal do Paraná (UTFPR), Graduate Program in Bioscience Technologies, Toledo, Paraná 85902-490, Brazil.ORCID https://orcid.org/0000-0003-2288-4997

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Silver nanoparticles synthesized via fungal-mediated processes represent an innovative and environmentally sustainable alternative to conventional chemical methods, reducing toxicity and ecological risks without compromising their antimicrobial activity, particularly against multidrug-resistant bacteria. This study aimed to optimize the synthesis of silver nanoparticles using chemical and biological approaches, characterize their physicochemical properties, and evaluate their antibacterial efficacy. Chemical synthesis employed sodium borohydride and carboxymethylcellulose, optimized via factorial design, with optimal conditions determined as 0.7 g L

Identifiers

PMID41078831
PMCPMC12508969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.